Ada Marta Fejerman -

Born in 2005, Ada Marta Fejerman is the daughter of the celebrated Argentine musician and cultural icon Andy Chango and acclaimed photographer Cristina Esperanza. From her earliest days, she was surrounded by legends of the music and literary worlds. This unique upbringing granted her an expansive, almost boundless perspective on creative expression. Rather than simply following in the footsteps of her famous father, Ada set out to forge her own sonic universe and completely distinct artistic identity. The Birth of "SUA": A Sonic Alter-Ego

Following her parents' separation around 2010, Ada Marta remained in Madrid with her mother. Despite the breakup, Emma Suárez generously allowed Andy Chango to temporarily live in the same household for a period so that he could remain deeply involved in Ada Marta's day-to-day upbringing, ensuring she grew up with a strong connection to both her Spanish and Argentine roots. Ada Marta shares a remarkably close, friendship-like bond with her mother, with whom she is frequently spotted enjoying low-key cultural events in Spain. Public Appearances and the Next Generation Ada Marta Fejerman

Fejerman’s work has consistently shown that Latina women with higher levels of Indigenous American ancestry tend to have a lower risk of breast cancer compared to those with higher European ancestry. This finding has prompted further research into the specific genetic variants that might be protective and how they interact with lifestyle factors like reproductive history and diet. Advocacy for Diversity in Genomic Research Born in 2005, Ada Marta Fejerman is the

Ada Marta shrugged. “Ghosts choose me.” Rather than simply following in the footsteps of

However, Fejerman is more than a lab researcher; she is a prominent advocate for diversity in genomic research. For decades, genome-wide association studies (GWAS) were conducted almost exclusively on individuals of European descent. Fejerman has been a vocal critic of this "genomic gap," arguing that excluding diverse populations leads to inaccurate risk assessments and exacerbates health inequities. Her leadership in initiatives like the San Francisco Bay Area Breast Cancer Study and her current role at the UC Davis Comprehensive Cancer Center focus on building large-scale cohorts of Latin American women to ensure that the benefits of precision medicine reach everyone.

To address the lack of diversity in genomic research, she leads several international efforts: